On September 10, 2026 Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, reported its participation in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

September 16, 2026
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
10:30 a.m. ET – fireside chat

September 23, 2026
Stifel 2026 Virtual Immunology and Inflammation Forum
12:30 p.m. ET – fireside chat

A simultaneous webcast of both events will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

(Press release, Nkarta, SEP 10, 2026, View Source [SID1234670733])